Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers

Blood

Volumn 118, Issue 7, 2011, Pages 1877-1884

  Rossi, Edmund A ^a,b   Rossi, Diane L ^b   Cardillo, Thomas M ^b   Stein, Rhona ^c   Goldenberg, David M ^c   Chang, Chien Hsing ^a,b  

^a IBC Pharmaceuticals Inc   (United States)

^b IMMUNOMEDICS INC   (United States)

^c CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; C2 2B 2B INTERFERON ALPHA MONOCLONAL ANTIBODY; CD20 ANTIGEN; HLA DR ANTIGEN; MONOCLONAL ANTIBODY; PEGINTERFERON ALPHA2A; STAT1 PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; LYMPHOMA; MOLECULAR DOCKING; MOUSE; MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT;

EID: 80051867145     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-03-343145     Document Type: Article

References (38)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225- 249.
2. Armitage A.E., Armitage J.D., Armitage J.O. Alphainterferon for relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant. 2006;38(10):701-702.
3. Armitage J.O., Coiffier B. Activity of interferonalpha in relapsed patients with diffuse large B-cell and peripheral T-cell non-Hodgkin's lymphoma. Ann Oncol. 2000;11(3):359-361. (Pubitemid 30214677)
4. Davis T.A., Maloney D.G., Grillo-Lopez A.J., et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. Clin Cancer Res. 2000;6(7):2644-2652. (Pubitemid 30482099)
5. Kimby E., Jurlander J., Geisler C., et al. Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group. Leuk Lymphoma. 2008;49(1): 102-112. (Pubitemid 351146889)
6. Ahmed S., Rai K.R. Interferon in the treatment of hairy-cell leukemia. Best Pract Res Clin Haematol. 2003;16(1):69-81.
7. Baccarani M., Rosti G., De Vivo A., et al. A randomized study of interferon-alpha versus interferonalpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood. 2002;99(5):1527-1535. (Pubitemid 34533021)
8. Khoo T.L., Vangsted A.J., Joshua D., Gibson J. Interferon- alpha in the treatment of multiple myeloma. Curr Drug Targets. 2011;12(3):437-446.
9. Stein R., Gupta P., Chen X., et al. Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyper-activation of ERK and JNK MAP kinase signaling pathways. Blood. 2010;115(25):5180- 5190.
10. Smith L.M., Petty H.R., Parham P., McConnell H.M. Cell surface properties of HLA antigens on Epstein- Barr virus-transformed cell lines. Proc Natl Acad Sci U S A. 1982;79(2):608-612. (Pubitemid 12137760)
11. Stein R., Qu Z., Chen S., et al. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab. Blood. 2006;108(8):2736- 2744.
12. Chang C.H., Rossi E.A., Goldenberg D.M. The dock and lock method: A novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity. Clin Cancer Res. 2007;13(18 Pt 2):5586s-5591s. (Pubitemid 47510391)
13. Rossi E.A., Goldenberg D.M., Cardillo T.M., et al. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci U S A. 2006;103(18):6841-6846.
14. Rossi E.A., Goldenberg D.M., Cardillo T.M., Stein R., Chang C.H. CD20-targeted tetrameric interferonalpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood. 2009; 114(18):3864-3871.
15. Rossi E.A., Rossi D.L., Stein R., Goldenberg D.M., Chang C.H. A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells. Cancer Res. 2010;70(19):7600- 7609.
16. Rossi E.A., Goldenberg D.M., Cardillo T.M., Stein R., Chang CH. Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma. Blood. 2009;113(24):6161-6171.
17. Rossi E.A., Goldenberg D.M., Cardillo T.M., et al. Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics. Cancer Res. 2008;68(20):8384-8392.
18. Adolf G.R., Kalsner I., Ahorn H., Maurer-Fogy I., Cantell K. Natural human interferon-alpha 2 is O-glycosylated. Biochem J. 1991;276 (Pt 2)511- 518.
19. Arulampalam V., Kolosenko I., Hjortsberg L., et al. Activation of STAT1 is required for interferon-alpha- mediated cell death. Exp Cell Res. 2011; 317(1):9-19.
20. Oancea M., Mani A., Hussein M.A., Almasan A. Apoptosis of multiple myeloma. Int J Hematol. 2004; 80(3):224-231. (Pubitemid 39410928)
21. Belardelli F., Ferrantini M., Proietti E., Kirkwood J.M. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002;13(2): 119-134. (Pubitemid 34229387)
22. Huang T.H., Chintalacharuvu K.R., Morrison S.L. Targeting IFN-alpha to B cell lymphoma by a tumor- specific antibody elicits potent antitumor activities. J Immunol. 2007;179(10):6881-6888.
23. Kramer M.J., Dennin R., Kramer C., et al. Cell and virus sensitivity studies with recombinant human alpha interferons. J Interferon Res. 1983;3(4): 425-435. (Pubitemid 14177467)
24. Weck P.K., Apperson S., May L., Stebbing N. Comparison of the antiviral activities of various cloned human interferon-alpha subtypes in mammalian cell cultures. J Gen Virol. 1981;57(Pt 1):233-237. (Pubitemid 12180317)
25. Bowman T., Garcia R., Turkson J., Jove R. STATs in oncogenesis. Oncogene. 2000;19(21):2474- 2488.
26. Catlett-Falcone R., Landowski T.H., Oshiro M.M., et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10(1):105-115. (Pubitemid 29077388)
27. Alas S., Bonavida B. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis. Clin Cancer Res. 2003;9(1):316-326. (Pubitemid 36109748)
28. Chin Y.E., Kitagawa M., Kuida K., Flavell R.A., Fu X.Y. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol Cell Biol. 1997;17(9):5328-5337. (Pubitemid 27357631)
29. Kumar A., Commane M., FlickingerT.W., Horvath C.M., Stark G.R. Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases. Science. 1997;278(5343):1630-1632. (Pubitemid 27516283)
30. Lee K.Y., Anderson E., Madani K., Rosen G.D. Loss of STAT1 expression confers resistance to IFNgamma- induced apoptosis in ME180 cells. FEBS Lett. 1999;459(3):323-326. (Pubitemid 29467361)
31. Dimberg L.Y., Dimberg A.I., Ivarsson K., et al. Ectopic and IFN-induced expression of Fas overcomes resistance to Fas-mediated apoptosis in multiple myeloma cells. Blood. 2005;106(4):1346- 1354.
32. Thyrell L., Arulampalam V., Hjortsberg L., et al. Interferon alpha induces cell death through interference with interleukin 6 signaling and inhibition of STAT3 activity. Exp Cell Res. 2007;313(19):4015- 4024.
33. Xuan C., Steward K.K., Timmerman J.M., Morrison S.L. Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. Blood. 2010;115(14): 2864-2871.
34. Bridges S.H., Kruisbeek A.M., Longo D.L. Selective in vivo antitumor effects of monoclonal anti-I-A antibody on B cell lymphoma. J Immunol. 1987; 139(12):4242-4249. (Pubitemid 18013726)
35. Stein R., Balkman C., Chen S., et al. Evaluation of anti-human leukocyte antigen-DR monoclonal antibody therapy in spontaneous canine lymphoma. Leuk Lymphoma. 2011;52(2):273-284.
36. Rech J., Repp R., Rech D., et al. A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: A pilot study. Leuk Lymphoma. 2006; 47(10):2147-2154. (Pubitemid 44650092)
37. Van der Kolk L.E., Grillo-Lopez A.J., Baars J.W., Hack C.E., Van Oers M.H. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol. 2001;115(4):807-811. (Pubitemid 34042897)
38. Shi J.D., Bullock C., Hall W.C., et al. In vivo pharmacodynamic effects of Hu1D10 (remitogen), a humanized antibody reactive against a polymorphic determinant of HLA-DR expressed on B cells. Leuk Lymphoma. 2002;43(6):1303-1312. (Pubitemid 34537977)